Last reviewed · How we verify
Demekarium Bromide (DEMECARIUM)
Demekarium Bromide (DEMECARIUM) is a small molecule drug that targets Acetylcholinesterase, an enzyme involved in the breakdown of acetylcholine. Originally developed and currently owned, it was FDA approved in 1959 for the treatment of glaucoma. As an off-patent medication, it is no longer under patent protection and has no generic manufacturers. Demekarium Bromide works by inhibiting the enzyme Acetylcholinesterase, thereby increasing the levels of acetylcholine in the body, which helps to reduce intraocular pressure in glaucoma patients. Its commercial status and key safety considerations are not well-documented.
At a glance
| Generic name | DEMECARIUM |
|---|---|
| Drug class | demecarium |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |